Cetrelimab not checked

Johnson & Johnson (Janssen) · JNJ-63723283

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
13 active
18 in total · 12 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Participants will receive cetrelimab 240 mg IV every 2 weeks.”In the company’s words, NCT03431350 on ClinicalTrials.gov
Tested for
Neoplasms (3 trials), Urinary Bladder Neoplasms (2 trials), Carcinoma, Non-Small-Cell Lung (2 trials), Bladder Cancer, Prostatic Neoplasms, Castration-Resistant, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Main trialPhase 3
“The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.”In the company’s words, NCT04658862 on ClinicalTrials.gov
Other names
JNJ-63723283

Other drugs for Neoplasms

All 2440 drugs for Neoplasms

Coming up7

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials18

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Dec 2026 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Phase 3Active, not recruiting 18 Sep 2029 A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Phase 2Active, not recruiting 31 Aug 2021 A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 2Active, not recruiting 3 Jul 2025 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Phase 1/2Active, not recruiting 30 Sep 2022 A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Phase 1/2Active, not recruiting 17 Nov 2023 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Phase 1/2Active, not recruiting 31 Jan 2027 A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Phase 1Active, not recruiting 14 Apr 2027 A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Phase 1Recruiting 31 Aug 2027 A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 1Recruiting 12 Jan 2028 A Study of JNJ-1761981 in Participants With Solid Tumors
Phase 1Recruiting 8 Nov 2028 A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Phase 2/3Completed 24 Oct 2018 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2Completed 4 Feb 2025 A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Phase 1Completed 11 Nov 2021 A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1Completed 4 Jul 2022 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Phase 1Completed 9 May 2023 A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
Phase 2Authorised not given A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN)
Phase 1/2Authorised not given CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cetrelimab

Following is part of Solo: you see every change to Cetrelimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in